Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.
Boshuizen J, Vredevoogd DW, Krijgsman O, Ligtenberg MA, Blankenstein S, de Bruijn B, Frederick DT, Kenski JCN, Parren M, Brüggemann M, Madu MF, Rozeman EA, Song JY, Horlings HM, Blank CU, van Akkooi ACJ, Flaherty KT, Boland GM, Peeper DS. Boshuizen J, et al. Among authors: horlings hm. Nat Commun. 2023 Feb 7;14(1):672. doi: 10.1038/s41467-023-35852-2. Nat Commun. 2023. PMID: 36750559 Free PMC article. No abstract available.
B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.
Steenbruggen TG, Wolf DM, Campbell MJ, Sanders J, Cornelissen S, Thijssen B, Salgado RA, Yau C, O-Grady N, Basu A, Bhaskaran R, Mittempergher L, Hirst GL, Coppe JP, Kok M, Sonke GS, van 't Veer LJ, Horlings HM. Steenbruggen TG, et al. Among authors: horlings hm. Breast Cancer Res. 2023 Oct 4;25(1):117. doi: 10.1186/s13058-023-01717-1. Breast Cancer Res. 2023. PMID: 37794508 Free PMC article.
Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer.
Mercan C, Balkenhol M, Salgado R, Sherman M, Vielh P, Vreuls W, Polónia A, Horlings HM, Weichert W, Carter JM, Bult P, Christgen M, Denkert C, van de Vijver K, Bokhorst JM, van der Laak J, Ciompi F. Mercan C, et al. Among authors: horlings hm. NPJ Breast Cancer. 2022 Nov 8;8(1):120. doi: 10.1038/s41523-022-00488-w. NPJ Breast Cancer. 2022. PMID: 36347887 Free PMC article.
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R. Berns K, et al. Among authors: horlings hm. Cancer Cell. 2007 Oct;12(4):395-402. doi: 10.1016/j.ccr.2007.08.030. Cancer Cell. 2007. PMID: 17936563 Free article. Clinical Trial.
Molecular profiles of progesterone receptor loss in human breast tumors.
Creighton CJ, Kent Osborne C, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chamness GC, Hilsenbeck SG, Lee AV, Schiff R. Creighton CJ, et al. Among authors: horlings hm. Breast Cancer Res Treat. 2009 Mar;114(2):287-99. doi: 10.1007/s10549-008-0017-2. Epub 2008 Apr 19. Breast Cancer Res Treat. 2009. PMID: 18425577 Free PMC article.
ESR1 gene amplification in breast cancer: a common phenomenon?
Horlings HM, Bergamaschi A, Nordgard SH, Kim YH, Han W, Noh DY, Salari K, Joosse SA, Reyal F, Lingjaerde OC, Kristensen VN, Børresen-Dale AL, Pollack J, van de Vijver MJ. Horlings HM, et al. Nat Genet. 2008 Jul;40(7):807-8; author reply 810-2. doi: 10.1038/ng0708-807. Nat Genet. 2008. PMID: 18583965 No abstract available.
128 results